Cached score snapshot

US.WST · West Pharmaceutical Services

110分制 44.5/110;5D動能v2 4/50;排序分 48.5/160 · Incomplete inputs

Ranking score 48.5/160
Main score 44.5/110
5D momentum v2 4/50
Rank #415
Setup grade F 19.7

Score breakdown

避免

Medium twelvedata

Score and price trend

F 19.7 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-11 07-16 08-18 09-21 10-16 $314.88$366.04$417.20 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.177 · anchors 120 +1.02% -0.76% / +3.82% 64.4% 1.6% Actual outcome pending · 1 / 3 bars observed
30D observation +8.65% +1.31% / +14.98% 78.6% 9.4% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +1.17% -0.82% / +3.96% 63.1% 1.9% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-06-11 → 2026-10-16 · 89 archived points · 2 Improving turn signal · 4 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 48.5
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 44.5/110 (避免)
5D momentum v2 4/50 (弱)
Score with momentum v2 48.5/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 347.229
ma50 350.119
close 339.97
prevClose 342.73
avgVolume20 445650
volumeRatio 0.82
changePercent -0.81

Metrics snapshot

close 339.97
volume 364100
changePercent -0.81

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 44.5/110
Main rating 避免
5D momentum v2 4/50
Score with momentum v2 48.5/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.2/5 · 一般

Dimension score 3.2/5
Dimension grade 一般

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0
roePoints 0.6
debtPoints 0.5
marginPoints 0.4
turnoverUsdM 123.7831
volumePoints 0.5
revenuePoints 0
dividendPoints 0.3
marketCapPoints 0.5

資金流 — 5.2/20 · 較差

Dimension score 5.2/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 0.8
obvPoints 0.8
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.WST
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 7.8/15 · 較差

Dimension score 7.8/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 4

details

qqq

ma20 717.5105
ma50 711.085
name QQQ
close 718.96
points 2

spy

ma20 769.053
ma50 756.8572
name SPY
close 770.19
points 2
source twelvedata+fred
atrPct 2.1178
atrPoints 3
cciPoints 0.8
vixPoints 0
marketTrendPoints 4

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 7.2/10 · 良好

Dimension score 7.2/10
Dimension grade 良好

Sub-items

position

score 1.4

details

atrPct 2.1178
turnoverUsdM 123.7831
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.WST
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 325.57

strength_details

ma_score 1
atr_score 2
rsi_score 1
macd_score 1
volume_score 1
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 4.2
take_profit_price 356.9685
target_multiplier 1.6
technical_strength 1.15
take_profit_percent 5
positionPoints 1.4
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.2357
diversificationPoints 2

技術信號 — 13.1/30 · 較差

Dimension score 13.1/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 1
macdPoints 0.8

vcpPayload

vcp_pass false
vcp_score 1
vcp_reason 跌縮量(近10日4日);靠近20日高位;Ready=N;Confirm=N

vcp_metrics

up_days 5
vol_ref 589273.3333
down_days 4
vcp_ready false
above_ma50 false
avg_vol_10 433490
avg_vol_20 452480
avg_vol_30 589273.3333
range_pct_10 0.0696
range_pct_20 0.0729
range_pct_30 0.103
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok true
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 0.7356
dist_to_20d_high 0.0564
down_shrink_days 4
breakout_level_20d 360.29
vcp_breakout_confirm false
contraction_ratio_10_30 0.6759
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 0
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.8

情緒分析 — 6/10 · 一般

Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 5
sentimentScoreRaw 1.5

sentimentData

raw {"id":141764056,"url":"https://finnhub.io/api/news?id=9cbab6f7eeb472c2721baa9d794caefdf1f134a429d3b369e43081e3c5e24adb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in […]","category":"company","datetime":1788792171,"headline":"Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?"}, {"id":141489657,"url":"https://finnhub.io/api/news?id=011ff4c15711d4617137fb441e555393f7c236e7aad1dd1035a302438078291e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"How West Pharmaceutical Services stock has been performing West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at US$339.97 on 3 September 2026. The company shows mixed returns over different periods, including gains over the past year alongside shorter term pullbacks. For West Pharmaceutical Services, the recent 1-day share price decline of 0.81% and 3.15% share price pullback over 30 days sit against a much stronger...","category":"company","datetime":1788574438,"headline":"West Pharmaceutical Services (WST) And The GLP 1 Story Behind Its Fair Value Gap"}, {"id":141365061,"url":"https://finnhub.io/api/news?id=08b30e8f2d2ce64488ba4d2766750978f0b02f1d6e4fa967975fe62bb434b20d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has delivered a strong 43.0% return over the past year, yet current checks suggest the stock is not a clear bargain. The Discounted Cash Flow (DCF) intrinsic value estimate sits close to the market price, while market multiples lean expensive. The 43.0% one year return highlights how strongly West Pharmaceutical Services has rewarded shareholders over this period and raises the bar for future expectations. Expectations for steady demand in its drug delivery and...","category":"company","datetime":1787738938,"headline":"West (WST) Stock May Be Trading At A Premium To Fair Value"}, {"id":141283987,"url":"https://finnhub.io/api/news?id=432e935bc9b76f655e09f8d5a14197353c48105f7c82d28ed670a6ebaeb67d39","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...","category":"company","datetime":1787263752,"headline":"West Pharmaceutical Services (WST) Gains Momentum On An Undervalued Narrative"}, {"id":141251978,"url":"https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.","category":"company","datetime":1786738980,"headline":"WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"}, {"id":141283980,"url":"https://finnhub.io/api/news?id=a5962998d4f217752a311f231a101d9a54f18875cf19b06e7e9d5089b383a838","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).","category":"company","datetime":1786726803,"headline":"West Pharmaceutical (WST) Upgraded to Buy: Here's Why"}, {"id":141209552,"url":"https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.","category":"company","datetime":1786643280,"headline":"WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"}, {"id":141209369,"url":"https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.","category":"company","datetime":1786643280,"headline":"Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"}
raw_source {"id":141766879,"url":"https://finnhub.io/api/news?id=fe2445e5a567ab197c9b5e13654a1b08bdc141906cb6c6abf6cdbf6e2265ae47","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.","category":"company","datetime":1788798000,"headline":"Philips Expands Women's Health Ultrasound Portfolio With New Transducer"}, {"id":141765278,"url":"https://finnhub.io/api/news?id=edb346d008cd354b074adb4681014a1d0066be0b7dd4cb2687854eefde08fd46","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.","category":"company","datetime":1788797520,"headline":"Novocure Reports Patient Data Exposure in Cybersecurity Incident"}, {"id":141764056,"url":"https://finnhub.io/api/news?id=9cbab6f7eeb472c2721baa9d794caefdf1f134a429d3b369e43081e3c5e24adb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in […]","category":"company","datetime":1788792171,"headline":"Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?"}, {"id":141489657,"url":"https://finnhub.io/api/news?id=011ff4c15711d4617137fb441e555393f7c236e7aad1dd1035a302438078291e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"How West Pharmaceutical Services stock has been performing West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at US$339.97 on 3 September 2026. The company shows mixed returns over different periods, including gains over the past year alongside shorter term pullbacks. For West Pharmaceutical Services, the recent 1-day share price decline of 0.81% and 3.15% share price pullback over 30 days sit against a much stronger...","category":"company","datetime":1788574438,"headline":"West Pharmaceutical Services (WST) And The GLP 1 Story Behind Its Fair Value Gap"}, {"id":141455383,"url":"https://finnhub.io/api/news?id=4521da65387b1edfe02b09e78249415553f3c231a03dbadecd6f07e26011f0f1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.","category":"company","datetime":1788550740,"headline":"Here's Why You Should Retain Cencora Stock in Your Portfolio for Now"}, {"id":141430965,"url":"https://finnhub.io/api/news?id=c2db62c3872d34b90c6d1100a4e38591088c4f8d82f43d7f898bd2659452d8a5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.","category":"company","datetime":1788533880,"headline":"Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now"}, {"id":141438250,"url":"https://finnhub.io/api/news?id=b32b18f70a2d6d97d3dfacec4155e52722a9bfb88b7fdbe7045235e8b9b7f072","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.","category":"company","datetime":1788533460,"headline":"Reasons to Hold HealthEquity Stock in Your Portfolio for Now"}, {"id":141438251,"url":"https://finnhub.io/api/news?id=5312f8fd75a4bee8e63dde36cadd4968060945ef5f913769b304adbf66335ba5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.","category":"company","datetime":1788533100,"headline":"Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC"}, {"id":141430966,"url":"https://finnhub.io/api/news?id=082f1e05ae3af0a526e2c1843b2f6cab5ec7e14a8c1cb1c2413f010a199696d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.","category":"company","datetime":1788532620,"headline":"Cencora Launches Cell and Gene Therapy Enablement for Health Systems"}, {"id":141402952,"url":"https://finnhub.io/api/news?id=3d3feccc82059226879876f1951569b64ecda9577a6127905cd7eefbeb5eb152","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.","category":"company","datetime":1788457140,"headline":"Reasons to Hold Veeva Systems Stock in Your Portfolio for Now"}, {"id":141402704,"url":"https://finnhub.io/api/news?id=b3b1ef4df8c77bd564b8c103e476159f06b03899b3c6c49a40a0d45a15c635c7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.","category":"company","datetime":1788457020,"headline":"Stryker Launches FDA-Cleared Apple Vision Pro Surgical App"}, {"id":141398492,"url":"https://finnhub.io/api/news?id=0a5a7558a4cf4b37bac18752cf142d092082b3361d51500171eb622693dad88d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.","category":"company","datetime":1788441720,"headline":"Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now"}, {"id":141380177,"url":"https://finnhub.io/api/news?id=9111bc075f64a710a804e3e1504b76b776d99dab739d9aa15d392491ccdd05f7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.","category":"company","datetime":1788377400,"headline":"Reasons to Retain Hims & Hers Stock in Your Portfolio for Now"}, {"id":141380178,"url":"https://finnhub.io/api/news?id=2b8d1aacd8f484827e4d64710c3d4f8e5e1c531af9bc90fd4134f334d7300c3e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.","category":"company","datetime":1788373980,"headline":"Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition"}, {"id":141379713,"url":"https://finnhub.io/api/news?id=86e15f8323c03c1ac87c4de0202df6bd8977a871e3b91cae624801d8ffb2b26d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.","category":"company","datetime":1788366660,"headline":"Here's Why You Should Add Merit Medical Stock to Your Portfolio Now"}, {"id":141379715,"url":"https://finnhub.io/api/news?id=2fd36efae43a9563f6f9269b884a90404cb97202438be101b33968a24fd368ef","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"GE HealthCare's Photonova Spectra gains CE Mark, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets.","category":"company","datetime":1788364440,"headline":"GEHC Wins CE Mark for Photonova Spectra, Expands International Reach"}, {"id":141376576,"url":"https://finnhub.io/api/news?id=3087b93c69dd0c1382b67f57ad43ee3fd98c8177a77c3279ec1cfac9960e9de0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.","category":"company","datetime":1788348983,"headline":"1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Ignore"}, {"id":141370222,"url":"https://finnhub.io/api/news?id=cdcf9a93a89cbc3d32d6f4047a7b2d7e69a9f399531c2f750a7dc6f9b4c46f75","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.","category":"company","datetime":1788281660,"headline":"1 Mid-Cap Stock on Our Buy List and 2 Facing Headwinds"}, {"id":141362435,"url":"https://finnhub.io/api/news?id=407196573d8a1a2c48daa3958ab0bce257f19da1b9b417899a5474c3419272a2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.","category":"company","datetime":1788275400,"headline":"Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio"}, {"id":141365052,"url":"https://finnhub.io/api/news?id=79711d7e0d41b4b20dc05cfd0d86c27dff7798c4a6e4a186ede8f489823bf6e8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.","category":"company","datetime":1788199920,"headline":"TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences"}, {"id":141364550,"url":"https://finnhub.io/api/news?id=c765372856fc2104c5ca9882f08fc39c84792d17ca317ff6996861c9bc875024","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"GEHC expands its Vivid cardiovascular ultrasound portfolio with three systems featuring AI tools and cSound imaging for varied care settings.","category":"company","datetime":1788190500,"headline":"GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems"}, {"id":141364000,"url":"https://finnhub.io/api/news?id=37a72908f114871f1a4dad46f9fc801a4f8980f63b77c0174b1008921028a865","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.","category":"company","datetime":1787935140,"headline":"CVRx Secures Devoted Health Coverage for Barostim Therapy"}, {"id":141365055,"url":"https://finnhub.io/api/news?id=dc321dc028f2ca7f2718a9d3d36cde495b8ab20285726cd7afe32f57df8136c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1787934623,"headline":"Why Is Align Technology (ALGN) Down 8.4% Since Last Earnings Report?"}, {"id":141365056,"url":"https://finnhub.io/api/news?id=5460fe93725161c219a1292541cb7aa50f6b6416a239893b11e43b8843634700","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.","category":"company","datetime":1787934120,"headline":"Natera & Angiex Partner to Evaluate AGX101 Response With Signatera"}, {"id":141336283,"url":"https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.","category":"company","datetime":1787894920,"headline":"Best Dividend Aristocrats For September 2026"}, {"id":141365057,"url":"https://finnhub.io/api/news?id=756d5aef28e74c9c83a7a2fc14505ee828b3098c9e9b9b5a632e25dcfe05c983","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.","category":"company","datetime":1787850547,"headline":"1 Healthcare Stock with Exciting Potential and 2 We Avoid"}, {"id":141364236,"url":"https://finnhub.io/api/news?id=5e22d4a74cec5831ef1bd013a9cb7f136d6596bc1e6054a8fc66b2fcd85827ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"VEEV's Q2 fiscal 2027 earnings and revenues top estimates, while strong Vault CRM momentum and a raised full-year outlook drive shares higher.","category":"company","datetime":1787848260,"headline":"Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock Up"}, {"id":141362487,"url":"https://finnhub.io/api/news?id=859e66a15a81fed71b31f1f47807c408b556a8a74534b8edfe4ea2da17ed01a0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.","category":"company","datetime":1787847720,"headline":"McKesson to Acquire Precision Medicine Group to Strengthen Services"}, {"id":141365049,"url":"https://finnhub.io/api/news?id=fdcaa3cfb19702f45b6e986c57935c07abb4c90b325fc1932b5780935c75a608","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Are Wall Street analysts favoring West Pharmaceutical’s stock now as GLP-1 drugs gain prominence?","category":"company","datetime":1787842705,"headline":"Are Wall Street Analysts Predicting West Pharmaceutical Stock Will Climb or Sink?"}, {"id":141365050,"url":"https://finnhub.io/api/news?id=b1d426faf4d8888f1998c7fe527b87639e2e23b3a82f028dbc9ea66a4c95313c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences:","category":"company","datetime":1787778000,"headline":"West to Participate in Upcoming Investor Conferences"}, {"id":141365060,"url":"https://finnhub.io/api/news?id=a1473b28ba4a6835fe121a1d8f9ed05bd061c5d3cdc3db5ada00e563a05ec31c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.","category":"company","datetime":1787761620,"headline":"DVA & Humana Expand Value-Based Care for Kidney Disease Patients"}, {"id":141365061,"url":"https://finnhub.io/api/news?id=08b30e8f2d2ce64488ba4d2766750978f0b02f1d6e4fa967975fe62bb434b20d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has delivered a strong 43.0% return over the past year, yet current checks suggest the stock is not a clear bargain. The Discounted Cash Flow (DCF) intrinsic value estimate sits close to the market price, while market multiples lean expensive. The 43.0% one year return highlights how strongly West Pharmaceutical Services has rewarded shareholders over this period and raises the bar for future expectations. Expectations for steady demand in its drug delivery and...","category":"company","datetime":1787738938,"headline":"West (WST) Stock May Be Trading At A Premium To Fair Value"}, {"id":141363823,"url":"https://finnhub.io/api/news?id=9c8b2f0475dfd629297bfae048b5d5f5ea0c0283c0bbe783b6963f9920c593ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Forget the humanoid robots for a minute; the most potent catalyst for the stock may already be hitting the streets, and it's growing exponentially.","category":"company","datetime":1787694070,"headline":"The Real Engine That Could Power Tesla Stock Higher"}, {"id":141362500,"url":"https://finnhub.io/api/news?id=c97396ca69cebd061cfc6360bafae78a6e230404b8a15b7da204581678be53e6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.","category":"company","datetime":1787677260,"headline":"Here's Why You Should Retain McKesson Stock in Your Portfolio for Now"}, {"id":141365064,"url":"https://finnhub.io/api/news?id=218622df49e57bcb62f12e212d22c011b986f0026c491e74060aa71012eeb063","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.","category":"company","datetime":1787676780,"headline":"Bausch + Lomb Advances Two First-in-Class Eye Health Therapies"}, {"id":141365065,"url":"https://finnhub.io/api/news?id=daff439d6cfbe0157d297e8035a9ba4aaca1d87274cf56c8e3df3b7f89708834","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.","category":"company","datetime":1787600820,"headline":"Reasons to Retain Doximity Stock in Your Portfolio for Now"}, {"id":141363645,"url":"https://finnhub.io/api/news?id=264a19181593f4971980165e459392bd4e0b8e274225be280b6620bad4285ede","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"CAH enters fiscal 2027 with strong specialty growth, but IRA pricing changes, GMPD challenges and heavy CapEx pose risks.","category":"company","datetime":1787600820,"headline":"Reasons to Retain Cardinal Health Stock in Your Portfolio for Now"}, {"id":141365067,"url":"https://finnhub.io/api/news?id=b5d18418be2a63dc83a03a7aa549a68160521026a35a1dc8d1106f644c06c648","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"AMN Healthcare's 2026 surge is backed by rebounding nurse and allied demand, stronger execution and persistent healthcare workforce shortages.","category":"company","datetime":1787599380,"headline":"AMN Stock Rallies Nearly 119% YTD: What's Behind the Momentum?"}, {"id":141283982,"url":"https://finnhub.io/api/news?id=c4b2da463c6f09a31ce8e17d294cbf1644931a45b43de4a4e12c8f1e77ee8f38","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.","category":"company","datetime":1787330760,"headline":"Here's Why You Should Retain Inogen Stock in Your Portfolio for Now"}, {"id":141278125,"url":"https://finnhub.io/api/news?id=c4219d4c8cc06018c3099f6575c54f4f5c3fca8777f4943262f105bf447c2dec","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.","category":"company","datetime":1787330580,"headline":"Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update"}, {"id":141283984,"url":"https://finnhub.io/api/news?id=b75563b5894b58e0887a3679e9fdda1971893a4221c73767729b846b337b105a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.","category":"company","datetime":1787330040,"headline":"INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?"}, {"id":141283985,"url":"https://finnhub.io/api/news?id=b73e213a06b8ca1cf8c2e1fb47c041c4ea799d097e88e7a558e805c84d3ec268","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.","category":"company","datetime":1787329800,"headline":"BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?"}, {"id":141279656,"url":"https://finnhub.io/api/news?id=5f941718a2b3dcd6c642c392d28f14263bd1e17229ca84c001ef41096bad7251","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.","category":"company","datetime":1787328720,"headline":"Here's Why You Should Hold Stryker Stock in Your Portfolio for Now"}, {"id":141283987,"url":"https://finnhub.io/api/news?id=432e935bc9b76f655e09f8d5a14197353c48105f7c82d28ed670a6ebaeb67d39","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...","category":"company","datetime":1787263752,"headline":"West Pharmaceutical Services (WST) Gains Momentum On An Undervalued Narrative"}, {"id":141281778,"url":"https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.","category":"company","datetime":1787246580,"headline":"BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"}, {"id":141283989,"url":"https://finnhub.io/api/news?id=06ef2c3b0c310a88b2928dc5b444a63ea76f2997d316a233b82b79a982d0782e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.","category":"company","datetime":1787246340,"headline":"Here's Why You Should Add INSP Stock to Your Portfolio Now"}, {"id":141266860,"url":"https://finnhub.io/api/news?id=db611a64fbf03b230be4b5b782e1bab7a0378c9f276b9bc20f8b0c7c17ff967e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.","category":"company","datetime":1787246040,"headline":"MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor"}, {"id":141271747,"url":"https://finnhub.io/api/news?id=a411d7c50ee1158e49ad68a8649589e2aaab44386f5c689d45e85d64c9b6f354","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.","category":"company","datetime":1787162160,"headline":"SNN Advances Surgical Robotics Through Imperial College Partnership"}, {"id":141283992,"url":"https://finnhub.io/api/news?id=37eb4fb3fb259704bc8889e42d9c66402dc8110e9f56566c62af937ffc38bd2e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.","category":"company","datetime":1787162100,"headline":"HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?"}, {"id":141279330,"url":"https://finnhub.io/api/news?id=30e482ac66f335fd06f9335323ecea233f86b3fec37689483b7273b323f2c7d1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.","category":"company","datetime":1787161080,"headline":"Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific"}, {"id":141283994,"url":"https://finnhub.io/api/news?id=7118fcfc455dcfff25cf8dd09c68938daf08dd78c9ed045f17f2c2487c7c2d8d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.","category":"company","datetime":1787152500,"headline":"Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now"}, {"id":141250273,"url":"https://finnhub.io/api/news?id=4f4d8cd3325945129135da552aa9f2af17f3d76a9331ac1cf5b18cfb4c48d155","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.","category":"company","datetime":1787068920,"headline":"Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery"}, {"id":141250274,"url":"https://finnhub.io/api/news?id=1a975a5def559bb06a4ecfcda3aecee05a660ede0187e55aaffd5aa1794c5c13","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.","category":"company","datetime":1786997100,"headline":"Here's Why You Should Retain CONMED Stock in Your Portfolio Now"}, {"id":141250275,"url":"https://finnhub.io/api/news?id=72aa3033993c9773bbace7800f1af4af161f6496b542780f6d21fdea95613697","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.","category":"company","datetime":1786985040,"headline":"Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer"}, {"id":141251978,"url":"https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.","category":"company","datetime":1786738980,"headline":"WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"}, {"id":141283980,"url":"https://finnhub.io/api/news?id=a5962998d4f217752a311f231a101d9a54f18875cf19b06e7e9d5089b383a838","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).","category":"company","datetime":1786726803,"headline":"West Pharmaceutical (WST) Upgraded to Buy: Here's Why"}, {"id":141250277,"url":"https://finnhub.io/api/news?id=4d66f96c7426611bc85ae63ebd3054a79571355183b4b1651d55d3f64e7b113d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.","category":"company","datetime":1786723500,"headline":"iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform"}, {"id":141209552,"url":"https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.","category":"company","datetime":1786643280,"headline":"WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"}, {"id":141209369,"url":"https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.","category":"company","datetime":1786643280,"headline":"Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"}, {"id":141209368,"url":"https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.","category":"company","datetime":1786643280,"headline":"WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"}, {"id":141202468,"url":"https://finnhub.io/api/news?id=d0e7e846d43e052f5cf2cc75222b2e19cdf44371cf038926785d5e1b34db15a4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.","category":"company","datetime":1786549260,"headline":"Here's Why You Should Add BrightSpring Stock to Your Portfolio Now"}, {"id":141202469,"url":"https://finnhub.io/api/news?id=e0277f3fb832d7629b5cfa40809a7c12d4b0dd92ab901d8e20bba9889d3940ae","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.","category":"company","datetime":1786548120,"headline":"NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up"}, {"id":141202470,"url":"https://finnhub.io/api/news?id=d905b87da679e4ea18aee242da05c8b20d2574455accbd89241960814059c104","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...","category":"company","datetime":1786518635,"headline":"West (WST) Stock Looks Overvalued After A 47% One Year Run"}, {"id":141202034,"url":"https://finnhub.io/api/news?id=c70632c2f9259acf971a4ff2e21f3a79f70231e7041cbbc36844dbb90356e0cf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.","category":"company","datetime":1786465260,"headline":"CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up"}, {"id":141202035,"url":"https://finnhub.io/api/news?id=5b2009080943f484ca312cf2ddae85582953343181666e7127ac9f3833e34b70","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.","category":"company","datetime":1786461600,"headline":"RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised"}, {"id":141177784,"url":"https://finnhub.io/api/news?id=2b214d626c55d69f3321fcb009f6866c20e2d848f4d640c809751929b9c57eb4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.","category":"company","datetime":1786380840,"headline":"Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut"}, {"id":141176776,"url":"https://finnhub.io/api/news?id=51215d10973a1d3873da231aeeefd48c6bc09a21e18da33bfd7c86363e77526d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"WST","summary":"IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.","category":"company","datetime":1786379820,"headline":"iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised"}, {"id":141164828,"url":"https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"WST","summary":"I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.","category":"company","datetime":1786243803,"headline":"Top 50 High-Quality Dividend Growth Stocks For August 2026"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 5
recomputed_at_score true
sentiment_score_raw 1.5
source_article_count 68
discarded_article_count 58
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.2 5/110 64% 3.2
資金流 5.2 20/110 26% 5.2
市場環境 7.8 15/110 52% 7.8
催化劑 2 20/110 10% 2
風險管理 7.2 10/110 72% 7.2
技術信號 13.1 30/110 43.67% 13.1
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 4/50
ret_5d 0.0074
max_score 50
max_total 50
raw_total 4
vcp_bonus 0
vol_ratio 0.8047
ret_points 4
vol_points 0
range_ratio 0.4217
volat_points 0
day_range_pct 0.0086
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 0
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.1178
turnoverUsdM 123.7831
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.WST
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 325.57

strength_details

ma_score 1
atr_score 2
rsi_score 1
macd_score 1
volume_score 1
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 4.2
take_profit_price 356.9685
target_multiplier 1.6
technical_strength 1.15
take_profit_percent 5
positionPoints 1.4
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.2357
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.2/5分
資金流分析總分: 5.2/20分
市場環境分析總分: 7.8/15分
催化劑分析: 2/20分
風險管理總分: 7.2/10分
技術信號分析總分: 13.1/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 85.71
atr
atr 7.2
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.12
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -109.26
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.2423
kdj
d 26.35
j 25.95
k 26.22
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 超賣或超買風險
score 2
value 23.7
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value 8206100
recentSlope -47100
previousSlope 15690
rsi
value 41.66
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 349.5353
position SAR喺價上
distancePct 2.81
previousTrend 下降
ma50
value 350.119
macd
macd -1.9843
trend 看跌
signal -0.9485
histogram -1.0358
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 348.0044
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.82
score 4
avgVolume 445650
currentVolume 364100
derived
ma20 347.229
ma50 350.119
prevClose 342.73
avgVolume10 418790
avgVolume20 445650
changePercent -0.81
avgVolumeForScore 445650
ma_cross
ma20 347.229
ma50 350.119
rule Cursor_18.24 MA20/MA50 cross
cross 熊勢
score 0
prevMa20 347.934
prevMa50 350.2508
spreadPct 0.83
isVolumeBreakout false
bollinger
lower 336.9428
upper 357.5152
position 中間
rsi_short
value 35.81
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.82

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.1178339265229282,
        "turnoverUsdM": 123.78307700000002,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.WST",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 325.57,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.2,
      "take_profit_price": 356.9685,
      "target_multiplier": 1.6,
      "technical_strength": 1.15,
      "take_profit_percent": 5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.2356678530458565,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 48.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 44.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 347.229,
    "ma50": 350.119,
    "close": 339.97,
    "prevClose": 342.73,
    "avgVolume20": 445650,
    "volumeRatio": 0.82,
    "changePercent": -0.81
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": 0.007408065902154259,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.8046764497878359,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.42171797467335065,
      "volat_points": 0,
      "day_range_pct": 0.008559578786363408,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 48.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 64,
        "contribution": 3.2
      },
      {
        "raw": 5.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 26,
        "contribution": 5.2
      },
      {
        "raw": 7.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 52,
        "contribution": 7.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 13.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 43.67,
        "contribution": 13.1
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 44.5,
    "details": [
      "基本面分析總分: 3.2/5分",
      "資金流分析總分: 5.2/20分",
      "市場環境分析總分: 7.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 13.1/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.2,
      "資金流": 5.2,
      "市場環境": 7.8,
      "情緒分析": 6,
      "技術信號": 13.1,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.6,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 123.78307700000002,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.WST",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 717.5105010500001,
                "ma50": 711.0850000400001,
                "name": "QQQ",
                "close": 718.96002,
                "points": 2
              },
              "spy": {
                "ma20": 769.0529934000002,
                "ma50": 756.85720062,
                "name": "SPY",
                "close": 770.19,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.1178339265229282,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 5,
              "sentimentScoreRaw": 1.5
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141764056,
                "url": "https://finnhub.io/api/news?id=9cbab6f7eeb472c2721baa9d794caefdf1f134a429d3b369e43081e3c5e24adb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in […]",
                "category": "company",
                "datetime": 1788792171,
                "headline": "Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?"
              },
              {
                "id": 141489657,
                "url": "https://finnhub.io/api/news?id=011ff4c15711d4617137fb441e555393f7c236e7aad1dd1035a302438078291e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "How West Pharmaceutical Services stock has been performing West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at US$339.97 on 3 September 2026. The company shows mixed returns over different periods, including gains over the past year alongside shorter term pullbacks. For West Pharmaceutical Services, the recent 1-day share price decline of 0.81% and 3.15% share price pullback over 30 days sit against a much stronger...",
                "category": "company",
                "datetime": 1788574438,
                "headline": "West Pharmaceutical Services (WST) And The GLP 1 Story Behind Its Fair Value Gap"
              },
              {
                "id": 141365061,
                "url": "https://finnhub.io/api/news?id=08b30e8f2d2ce64488ba4d2766750978f0b02f1d6e4fa967975fe62bb434b20d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has delivered a strong 43.0% return over the past year, yet current checks suggest the stock is not a clear bargain. The Discounted Cash Flow (DCF) intrinsic value estimate sits close to the market price, while market multiples lean expensive. The 43.0% one year return highlights how strongly West Pharmaceutical Services has rewarded shareholders over this period and raises the bar for future expectations. Expectations for steady demand in its drug delivery and...",
                "category": "company",
                "datetime": 1787738938,
                "headline": "West (WST) Stock May Be Trading At A Premium To Fair Value"
              },
              {
                "id": 141283987,
                "url": "https://finnhub.io/api/news?id=432e935bc9b76f655e09f8d5a14197353c48105f7c82d28ed670a6ebaeb67d39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...",
                "category": "company",
                "datetime": 1787263752,
                "headline": "West Pharmaceutical Services (WST) Gains Momentum On An Undervalued Narrative"
              },
              {
                "id": 141251978,
                "url": "https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.",
                "category": "company",
                "datetime": 1786738980,
                "headline": "WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"
              },
              {
                "id": 141283980,
                "url": "https://finnhub.io/api/news?id=a5962998d4f217752a311f231a101d9a54f18875cf19b06e7e9d5089b383a838",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1786726803,
                "headline": "West Pharmaceutical (WST) Upgraded to Buy: Here's Why"
              },
              {
                "id": 141209552,
                "url": "https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"
              },
              {
                "id": 141209369,
                "url": "https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"
              }
            ],
            "raw_source": [
              {
                "id": 141766879,
                "url": "https://finnhub.io/api/news?id=fe2445e5a567ab197c9b5e13654a1b08bdc141906cb6c6abf6cdbf6e2265ae47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.",
                "category": "company",
                "datetime": 1788798000,
                "headline": "Philips Expands Women's Health Ultrasound Portfolio With New Transducer"
              },
              {
                "id": 141765278,
                "url": "https://finnhub.io/api/news?id=edb346d008cd354b074adb4681014a1d0066be0b7dd4cb2687854eefde08fd46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.",
                "category": "company",
                "datetime": 1788797520,
                "headline": "Novocure Reports Patient Data Exposure in Cybersecurity Incident"
              },
              {
                "id": 141764056,
                "url": "https://finnhub.io/api/news?id=9cbab6f7eeb472c2721baa9d794caefdf1f134a429d3b369e43081e3c5e24adb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in […]",
                "category": "company",
                "datetime": 1788792171,
                "headline": "Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?"
              },
              {
                "id": 141489657,
                "url": "https://finnhub.io/api/news?id=011ff4c15711d4617137fb441e555393f7c236e7aad1dd1035a302438078291e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "How West Pharmaceutical Services stock has been performing West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at US$339.97 on 3 September 2026. The company shows mixed returns over different periods, including gains over the past year alongside shorter term pullbacks. For West Pharmaceutical Services, the recent 1-day share price decline of 0.81% and 3.15% share price pullback over 30 days sit against a much stronger...",
                "category": "company",
                "datetime": 1788574438,
                "headline": "West Pharmaceutical Services (WST) And The GLP 1 Story Behind Its Fair Value Gap"
              },
              {
                "id": 141455383,
                "url": "https://finnhub.io/api/news?id=4521da65387b1edfe02b09e78249415553f3c231a03dbadecd6f07e26011f0f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.",
                "category": "company",
                "datetime": 1788550740,
                "headline": "Here's Why You Should Retain Cencora Stock in Your Portfolio for Now"
              },
              {
                "id": 141430965,
                "url": "https://finnhub.io/api/news?id=c2db62c3872d34b90c6d1100a4e38591088c4f8d82f43d7f898bd2659452d8a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.",
                "category": "company",
                "datetime": 1788533880,
                "headline": "Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now"
              },
              {
                "id": 141438250,
                "url": "https://finnhub.io/api/news?id=b32b18f70a2d6d97d3dfacec4155e52722a9bfb88b7fdbe7045235e8b9b7f072",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.",
                "category": "company",
                "datetime": 1788533460,
                "headline": "Reasons to Hold HealthEquity Stock in Your Portfolio for Now"
              },
              {
                "id": 141438251,
                "url": "https://finnhub.io/api/news?id=5312f8fd75a4bee8e63dde36cadd4968060945ef5f913769b304adbf66335ba5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.",
                "category": "company",
                "datetime": 1788533100,
                "headline": "Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC"
              },
              {
                "id": 141430966,
                "url": "https://finnhub.io/api/news?id=082f1e05ae3af0a526e2c1843b2f6cab5ec7e14a8c1cb1c2413f010a199696d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.",
                "category": "company",
                "datetime": 1788532620,
                "headline": "Cencora Launches Cell and Gene Therapy Enablement for Health Systems"
              },
              {
                "id": 141402952,
                "url": "https://finnhub.io/api/news?id=3d3feccc82059226879876f1951569b64ecda9577a6127905cd7eefbeb5eb152",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.",
                "category": "company",
                "datetime": 1788457140,
                "headline": "Reasons to Hold Veeva Systems Stock in Your Portfolio for Now"
              },
              {
                "id": 141402704,
                "url": "https://finnhub.io/api/news?id=b3b1ef4df8c77bd564b8c103e476159f06b03899b3c6c49a40a0d45a15c635c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.",
                "category": "company",
                "datetime": 1788457020,
                "headline": "Stryker Launches FDA-Cleared Apple Vision Pro Surgical App"
              },
              {
                "id": 141398492,
                "url": "https://finnhub.io/api/news?id=0a5a7558a4cf4b37bac18752cf142d092082b3361d51500171eb622693dad88d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.",
                "category": "company",
                "datetime": 1788441720,
                "headline": "Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now"
              },
              {
                "id": 141380177,
                "url": "https://finnhub.io/api/news?id=9111bc075f64a710a804e3e1504b76b776d99dab739d9aa15d392491ccdd05f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.",
                "category": "company",
                "datetime": 1788377400,
                "headline": "Reasons to Retain Hims & Hers Stock in Your Portfolio for Now"
              },
              {
                "id": 141380178,
                "url": "https://finnhub.io/api/news?id=2b8d1aacd8f484827e4d64710c3d4f8e5e1c531af9bc90fd4134f334d7300c3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.",
                "category": "company",
                "datetime": 1788373980,
                "headline": "Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition"
              },
              {
                "id": 141379713,
                "url": "https://finnhub.io/api/news?id=86e15f8323c03c1ac87c4de0202df6bd8977a871e3b91cae624801d8ffb2b26d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.",
                "category": "company",
                "datetime": 1788366660,
                "headline": "Here's Why You Should Add Merit Medical Stock to Your Portfolio Now"
              },
              {
                "id": 141379715,
                "url": "https://finnhub.io/api/news?id=2fd36efae43a9563f6f9269b884a90404cb97202438be101b33968a24fd368ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "GE HealthCare's Photonova Spectra gains CE Mark, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets.",
                "category": "company",
                "datetime": 1788364440,
                "headline": "GEHC Wins CE Mark for Photonova Spectra, Expands International Reach"
              },
              {
                "id": 141376576,
                "url": "https://finnhub.io/api/news?id=3087b93c69dd0c1382b67f57ad43ee3fd98c8177a77c3279ec1cfac9960e9de0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.",
                "category": "company",
                "datetime": 1788348983,
                "headline": "1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Ignore"
              },
              {
                "id": 141370222,
                "url": "https://finnhub.io/api/news?id=cdcf9a93a89cbc3d32d6f4047a7b2d7e69a9f399531c2f750a7dc6f9b4c46f75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.",
                "category": "company",
                "datetime": 1788281660,
                "headline": "1 Mid-Cap Stock on Our Buy List and 2 Facing Headwinds"
              },
              {
                "id": 141362435,
                "url": "https://finnhub.io/api/news?id=407196573d8a1a2c48daa3958ab0bce257f19da1b9b417899a5474c3419272a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SYK's planned ZuriMED acquisition adds the FiberLocker System, aiming to strengthen its shoulder portfolio and rotator cuff care capabilities.",
                "category": "company",
                "datetime": 1788275400,
                "headline": "Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio"
              },
              {
                "id": 141365052,
                "url": "https://finnhub.io/api/news?id=79711d7e0d41b4b20dc05cfd0d86c27dff7798c4a6e4a186ede8f489823bf6e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.",
                "category": "company",
                "datetime": 1788199920,
                "headline": "TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences"
              },
              {
                "id": 141364550,
                "url": "https://finnhub.io/api/news?id=c765372856fc2104c5ca9882f08fc39c84792d17ca317ff6996861c9bc875024",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "GEHC expands its Vivid cardiovascular ultrasound portfolio with three systems featuring AI tools and cSound imaging for varied care settings.",
                "category": "company",
                "datetime": 1788190500,
                "headline": "GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems"
              },
              {
                "id": 141364000,
                "url": "https://finnhub.io/api/news?id=37a72908f114871f1a4dad46f9fc801a4f8980f63b77c0174b1008921028a865",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.",
                "category": "company",
                "datetime": 1787935140,
                "headline": "CVRx Secures Devoted Health Coverage for Barostim Therapy"
              },
              {
                "id": 141365055,
                "url": "https://finnhub.io/api/news?id=dc321dc028f2ca7f2718a9d3d36cde495b8ab20285726cd7afe32f57df8136c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787934623,
                "headline": "Why Is Align Technology (ALGN) Down 8.4% Since Last Earnings Report?"
              },
              {
                "id": 141365056,
                "url": "https://finnhub.io/api/news?id=5460fe93725161c219a1292541cb7aa50f6b6416a239893b11e43b8843634700",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.",
                "category": "company",
                "datetime": 1787934120,
                "headline": "Natera & Angiex Partner to Evaluate AGX101 Response With Signatera"
              },
              {
                "id": 141336283,
                "url": "https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.",
                "category": "company",
                "datetime": 1787894920,
                "headline": "Best Dividend Aristocrats For September 2026"
              },
              {
                "id": 141365057,
                "url": "https://finnhub.io/api/news?id=756d5aef28e74c9c83a7a2fc14505ee828b3098c9e9b9b5a632e25dcfe05c983",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.",
                "category": "company",
                "datetime": 1787850547,
                "headline": "1 Healthcare Stock with Exciting Potential and 2 We Avoid"
              },
              {
                "id": 141364236,
                "url": "https://finnhub.io/api/news?id=5e22d4a74cec5831ef1bd013a9cb7f136d6596bc1e6054a8fc66b2fcd85827ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "VEEV's Q2 fiscal 2027 earnings and revenues top estimates, while strong Vault CRM momentum and a raised full-year outlook drive shares higher.",
                "category": "company",
                "datetime": 1787848260,
                "headline": "Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock Up"
              },
              {
                "id": 141362487,
                "url": "https://finnhub.io/api/news?id=859e66a15a81fed71b31f1f47807c408b556a8a74534b8edfe4ea2da17ed01a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.",
                "category": "company",
                "datetime": 1787847720,
                "headline": "McKesson to Acquire Precision Medicine Group to Strengthen Services"
              },
              {
                "id": 141365049,
                "url": "https://finnhub.io/api/news?id=fdcaa3cfb19702f45b6e986c57935c07abb4c90b325fc1932b5780935c75a608",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Are Wall Street analysts favoring West Pharmaceutical’s stock now as GLP-1 drugs gain prominence?",
                "category": "company",
                "datetime": 1787842705,
                "headline": "Are Wall Street Analysts Predicting West Pharmaceutical Stock Will Climb or Sink?"
              },
              {
                "id": 141365050,
                "url": "https://finnhub.io/api/news?id=b1d426faf4d8888f1998c7fe527b87639e2e23b3a82f028dbc9ea66a4c95313c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences:",
                "category": "company",
                "datetime": 1787778000,
                "headline": "West to Participate in Upcoming Investor Conferences"
              },
              {
                "id": 141365060,
                "url": "https://finnhub.io/api/news?id=a1473b28ba4a6835fe121a1d8f9ed05bd061c5d3cdc3db5ada00e563a05ec31c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.",
                "category": "company",
                "datetime": 1787761620,
                "headline": "DVA & Humana Expand Value-Based Care for Kidney Disease Patients"
              },
              {
                "id": 141365061,
                "url": "https://finnhub.io/api/news?id=08b30e8f2d2ce64488ba4d2766750978f0b02f1d6e4fa967975fe62bb434b20d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has delivered a strong 43.0% return over the past year, yet current checks suggest the stock is not a clear bargain. The Discounted Cash Flow (DCF) intrinsic value estimate sits close to the market price, while market multiples lean expensive. The 43.0% one year return highlights how strongly West Pharmaceutical Services has rewarded shareholders over this period and raises the bar for future expectations. Expectations for steady demand in its drug delivery and...",
                "category": "company",
                "datetime": 1787738938,
                "headline": "West (WST) Stock May Be Trading At A Premium To Fair Value"
              },
              {
                "id": 141363823,
                "url": "https://finnhub.io/api/news?id=9c8b2f0475dfd629297bfae048b5d5f5ea0c0283c0bbe783b6963f9920c593ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Forget the humanoid robots for a minute; the most potent catalyst for the stock may already be hitting the streets, and it's growing exponentially.",
                "category": "company",
                "datetime": 1787694070,
                "headline": "The Real Engine That Could Power Tesla Stock Higher"
              },
              {
                "id": 141362500,
                "url": "https://finnhub.io/api/news?id=c97396ca69cebd061cfc6360bafae78a6e230404b8a15b7da204581678be53e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.",
                "category": "company",
                "datetime": 1787677260,
                "headline": "Here's Why You Should Retain McKesson Stock in Your Portfolio for Now"
              },
              {
                "id": 141365064,
                "url": "https://finnhub.io/api/news?id=218622df49e57bcb62f12e212d22c011b986f0026c491e74060aa71012eeb063",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.",
                "category": "company",
                "datetime": 1787676780,
                "headline": "Bausch + Lomb Advances Two First-in-Class Eye Health Therapies"
              },
              {
                "id": 141365065,
                "url": "https://finnhub.io/api/news?id=daff439d6cfbe0157d297e8035a9ba4aaca1d87274cf56c8e3df3b7f89708834",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.",
                "category": "company",
                "datetime": 1787600820,
                "headline": "Reasons to Retain Doximity Stock in Your Portfolio for Now"
              },
              {
                "id": 141363645,
                "url": "https://finnhub.io/api/news?id=264a19181593f4971980165e459392bd4e0b8e274225be280b6620bad4285ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "CAH enters fiscal 2027 with strong specialty growth, but IRA pricing changes, GMPD challenges and heavy CapEx pose risks.",
                "category": "company",
                "datetime": 1787600820,
                "headline": "Reasons to Retain Cardinal Health Stock in Your Portfolio for Now"
              },
              {
                "id": 141365067,
                "url": "https://finnhub.io/api/news?id=b5d18418be2a63dc83a03a7aa549a68160521026a35a1dc8d1106f644c06c648",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "AMN Healthcare's 2026 surge is backed by rebounding nurse and allied demand, stronger execution and persistent healthcare workforce shortages.",
                "category": "company",
                "datetime": 1787599380,
                "headline": "AMN Stock Rallies Nearly 119% YTD: What's Behind the Momentum?"
              },
              {
                "id": 141283982,
                "url": "https://finnhub.io/api/news?id=c4b2da463c6f09a31ce8e17d294cbf1644931a45b43de4a4e12c8f1e77ee8f38",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.",
                "category": "company",
                "datetime": 1787330760,
                "headline": "Here's Why You Should Retain Inogen Stock in Your Portfolio for Now"
              },
              {
                "id": 141278125,
                "url": "https://finnhub.io/api/news?id=c4219d4c8cc06018c3099f6575c54f4f5c3fca8777f4943262f105bf447c2dec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.",
                "category": "company",
                "datetime": 1787330580,
                "headline": "Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update"
              },
              {
                "id": 141283984,
                "url": "https://finnhub.io/api/news?id=b75563b5894b58e0887a3679e9fdda1971893a4221c73767729b846b337b105a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.",
                "category": "company",
                "datetime": 1787330040,
                "headline": "INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?"
              },
              {
                "id": 141283985,
                "url": "https://finnhub.io/api/news?id=b73e213a06b8ca1cf8c2e1fb47c041c4ea799d097e88e7a558e805c84d3ec268",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.",
                "category": "company",
                "datetime": 1787329800,
                "headline": "BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?"
              },
              {
                "id": 141279656,
                "url": "https://finnhub.io/api/news?id=5f941718a2b3dcd6c642c392d28f14263bd1e17229ca84c001ef41096bad7251",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.",
                "category": "company",
                "datetime": 1787328720,
                "headline": "Here's Why You Should Hold Stryker Stock in Your Portfolio for Now"
              },
              {
                "id": 141283987,
                "url": "https://finnhub.io/api/news?id=432e935bc9b76f655e09f8d5a14197353c48105f7c82d28ed670a6ebaeb67d39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Recent share performance and business backdrop West Pharmaceutical Services (WST) has drawn investor attention after a period where the stock returned 0.1% over the past month and 11.6% over the past 3 months, against a backdrop of steady reported operations. The company reports annual revenue of US$3.3b and net income of US$564.9m, supported by two primary segments. Proprietary Products contribute US$2.7b and West Vantage, which sits within that portfolio, adds US$600.6m. See our latest...",
                "category": "company",
                "datetime": 1787263752,
                "headline": "West Pharmaceutical Services (WST) Gains Momentum On An Undervalued Narrative"
              },
              {
                "id": 141281778,
                "url": "https://finnhub.io/api/news?id=e7adcedb141ab46bd93163e2536b035f1d90bc75f1cf4cfe9ac78f80f75695ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.",
                "category": "company",
                "datetime": 1787246580,
                "headline": "BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study"
              },
              {
                "id": 141283989,
                "url": "https://finnhub.io/api/news?id=06ef2c3b0c310a88b2928dc5b444a63ea76f2997d316a233b82b79a982d0782e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.",
                "category": "company",
                "datetime": 1787246340,
                "headline": "Here's Why You Should Add INSP Stock to Your Portfolio Now"
              },
              {
                "id": 141266860,
                "url": "https://finnhub.io/api/news?id=db611a64fbf03b230be4b5b782e1bab7a0378c9f276b9bc20f8b0c7c17ff967e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.",
                "category": "company",
                "datetime": 1787246040,
                "headline": "MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor"
              },
              {
                "id": 141271747,
                "url": "https://finnhub.io/api/news?id=a411d7c50ee1158e49ad68a8649589e2aaab44386f5c689d45e85d64c9b6f354",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.",
                "category": "company",
                "datetime": 1787162160,
                "headline": "SNN Advances Surgical Robotics Through Imperial College Partnership"
              },
              {
                "id": 141283992,
                "url": "https://finnhub.io/api/news?id=37eb4fb3fb259704bc8889e42d9c66402dc8110e9f56566c62af937ffc38bd2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.",
                "category": "company",
                "datetime": 1787162100,
                "headline": "HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?"
              },
              {
                "id": 141279330,
                "url": "https://finnhub.io/api/news?id=30e482ac66f335fd06f9335323ecea233f86b3fec37689483b7273b323f2c7d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.",
                "category": "company",
                "datetime": 1787161080,
                "headline": "Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific"
              },
              {
                "id": 141283994,
                "url": "https://finnhub.io/api/news?id=7118fcfc455dcfff25cf8dd09c68938daf08dd78c9ed045f17f2c2487c7c2d8d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.",
                "category": "company",
                "datetime": 1787152500,
                "headline": "Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now"
              },
              {
                "id": 141250273,
                "url": "https://finnhub.io/api/news?id=4f4d8cd3325945129135da552aa9f2af17f3d76a9331ac1cf5b18cfb4c48d155",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.",
                "category": "company",
                "datetime": 1787068920,
                "headline": "Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery"
              },
              {
                "id": 141250274,
                "url": "https://finnhub.io/api/news?id=1a975a5def559bb06a4ecfcda3aecee05a660ede0187e55aaffd5aa1794c5c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.",
                "category": "company",
                "datetime": 1786997100,
                "headline": "Here's Why You Should Retain CONMED Stock in Your Portfolio Now"
              },
              {
                "id": 141250275,
                "url": "https://finnhub.io/api/news?id=72aa3033993c9773bbace7800f1af4af161f6496b542780f6d21fdea95613697",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.",
                "category": "company",
                "datetime": 1786985040,
                "headline": "Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer"
              },
              {
                "id": 141251978,
                "url": "https://finnhub.io/api/news?id=6a679e9dc3223f5f4d26900c4cb64486a33c4d0b9199983538ecbbe0d87ec892",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.",
                "category": "company",
                "datetime": 1786738980,
                "headline": "WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?"
              },
              {
                "id": 141283980,
                "url": "https://finnhub.io/api/news?id=a5962998d4f217752a311f231a101d9a54f18875cf19b06e7e9d5089b383a838",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1786726803,
                "headline": "West Pharmaceutical (WST) Upgraded to Buy: Here's Why"
              },
              {
                "id": 141250277,
                "url": "https://finnhub.io/api/news?id=4d66f96c7426611bc85ae63ebd3054a79571355183b4b1651d55d3f64e7b113d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.",
                "category": "company",
                "datetime": 1786723500,
                "headline": "iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform"
              },
              {
                "id": 141209552,
                "url": "https://finnhub.io/api/news?id=34adc642e70b4125762c74cf110e74280a03d2d2a3535b586404e3e00fa81af8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook"
              },
              {
                "id": 141209369,
                "url": "https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"
              },
              {
                "id": 141209368,
                "url": "https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"
              },
              {
                "id": 141202468,
                "url": "https://finnhub.io/api/news?id=d0e7e846d43e052f5cf2cc75222b2e19cdf44371cf038926785d5e1b34db15a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "BTSG's specialty, infusion and home health momentum support growth, while IRA pressure and customer exits may weigh on near-term margins.",
                "category": "company",
                "datetime": 1786549260,
                "headline": "Here's Why You Should Add BrightSpring Stock to Your Portfolio Now"
              },
              {
                "id": 141202469,
                "url": "https://finnhub.io/api/news?id=e0277f3fb832d7629b5cfa40809a7c12d4b0dd92ab901d8e20bba9889d3940ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.",
                "category": "company",
                "datetime": 1786548120,
                "headline": "NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up"
              },
              {
                "id": 141202470,
                "url": "https://finnhub.io/api/news?id=d905b87da679e4ea18aee242da05c8b20d2574455accbd89241960814059c104",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "West Pharmaceutical Services has delivered a strong 46.9% share price return over the past year, and the stock now sits in a zone where its intrinsic value estimate looks roughly in line with the market while several valuation checks flag a richer pricing backdrop. Over the last 12 months, West Pharmaceutical Services has returned 46.9%, which puts extra focus on whether that gain already reflects most of the company’s fundamental strengths. Following recent earnings updates that highlighted...",
                "category": "company",
                "datetime": 1786518635,
                "headline": "West (WST) Stock Looks Overvalued After A 47% One Year Run"
              },
              {
                "id": 141202034,
                "url": "https://finnhub.io/api/news?id=c70632c2f9259acf971a4ff2e21f3a79f70231e7041cbbc36844dbb90356e0cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "Cardinal Health beats fiscal Q4 EPS estimates as profit surges, while revenues miss; fiscal 2027 guidance points to continued earnings growth.",
                "category": "company",
                "datetime": 1786465260,
                "headline": "CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up"
              },
              {
                "id": 141202035,
                "url": "https://finnhub.io/api/news?id=5b2009080943f484ca312cf2ddae85582953343181666e7127ac9f3833e34b70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.",
                "category": "company",
                "datetime": 1786461600,
                "headline": "RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised"
              },
              {
                "id": 141177784,
                "url": "https://finnhub.io/api/news?id=2b214d626c55d69f3321fcb009f6866c20e2d848f4d640c809751929b9c57eb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.",
                "category": "company",
                "datetime": 1786380840,
                "headline": "Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut"
              },
              {
                "id": 141176776,
                "url": "https://finnhub.io/api/news?id=51215d10973a1d3873da231aeeefd48c6bc09a21e18da33bfd7c86363e77526d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "WST",
                "summary": "IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.",
                "category": "company",
                "datetime": 1786379820,
                "headline": "iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised"
              },
              {
                "id": 141164828,
                "url": "https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "WST",
                "summary": "I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.",
                "category": "company",
                "datetime": 1786243803,
                "headline": "Top 50 High-Quality Dividend Growth Stocks For August 2026"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 5,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.5,
            "source_article_count": 68,
            "discarded_article_count": 58
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 13.1,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日4日);靠近20日高位;Ready=N;Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 589273.3333333334,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 433490,
              "avg_vol_20": 452480,
              "avg_vol_30": 589273.3333333334,
              "range_pct_10": 0.06962373150572095,
              "range_pct_20": 0.07288878430449737,
              "range_pct_30": 0.10300914786598814,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7356348497018926,
              "dist_to_20d_high": 0.056399038097115065,
              "down_shrink_days": 4,
              "breakout_level_20d": 360.29001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6758985288986117
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.1178339265229282,
              "turnoverUsdM": 123.78307700000002,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.WST",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 325.57,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.2,
            "take_profit_price": 356.9685,
            "target_multiplier": 1.6,
            "technical_strength": 1.15,
            "take_profit_percent": 5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.2356678530458565,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.WST",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 7.2,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.12
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -109.26
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.2423
    },
    "kdj": {
      "d": 26.35,
      "j": 25.95,
      "k": 26.22,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 23.7
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 8206100,
      "recentSlope": -47100,
      "previousSlope": 15690
    },
    "rsi": 41.66,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 349.5353,
      "position": "SAR喺價上",
      "distancePct": 2.81,
      "previousTrend": "下降"
    },
    "ma50": 350.119,
    "macd": {
      "macd": -1.98430022899106,
      "trend": "看跌",
      "signal": -0.9484936595189029,
      "histogram": -1.0358065694721572
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 348.0044,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.82,
      "score": 4,
      "avgVolume": 445650,
      "currentVolume": 364100
    },
    "derived": {
      "ma20": 347.229,
      "ma50": 350.119,
      "prevClose": 342.73,
      "avgVolume10": 418790,
      "avgVolume20": 445650,
      "changePercent": -0.81,
      "avgVolumeForScore": 445650
    },
    "ma_cross": {
      "ma20": 347.229,
      "ma50": 350.119,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 347.934,
      "prevMa50": 350.2508,
      "spreadPct": 0.83,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 336.9428,
      "upper": 357.5152,
      "position": "中間"
    },
    "rsi_short": 35.81,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.82
    }
  }
}

Raw metrics JSON

{
  "close": 339.97,
  "volume": 364100,
  "changePercent": -0.81
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.